Clinical Trials Logo

Filter by:
NCT ID: NCT04715646 Active, not recruiting - Epilepsy Clinical Trials

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Start date: March 11, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.

NCT ID: NCT04714736 Completed - Clinical trials for Acute Coronary Syndromes

DyeVert System and Contrast-induced Acute Kidney Injury

REMEDIALIV
Start date: February 10, 2020
Phase: N/A
Study type: Interventional

The aim of the REnal Insufficiency Following Contrast MEDIA Administration TriaL IV (REMEDIAL IV) is to test whether the use of the DyeVert system is effective in reducing CI-AKI rate in ACS patients undergoing urgent/immediate (within 2 hours) invasive diagnostic and/or interventional cardiovascular procedures. The DyeVertâ„¢ system (Osprey Medical Inc., Minnetonka, MN, USA) is a novel device designed to reduce CM volume during coronary procedures, while maintaining fluoroscopic image quality. Patients with ACS scheduled for urgent/immediate coronary angiography/angioplasty will be enrolled and randomized into 2 groups: 1) DyeVert group (CM injection will be handled by the DyeVert TM system), and 2) Control group (CM injection will be carried out by a conventional manual injection syringe).

NCT ID: NCT04714580 Completed - Motor Activity Clinical Trials

The Animal Fun Program to Support the Motor Development of the Italian Pre-schoolers: a Case-Control Study

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

The present literature supports the importance of the motor activity since the early stages of the human development. The children with poor motor skills are at greater risk for psychosocial, internalizing, and metabolic diseases. In Italy data about obesity and inactivity are increasing, anyway there is lack of motor program for pre-schoolers. The movement program Animal Fun seems to be a valid tool to support these children. The aim of this study is to verify the feasibility of using Animal Fun with Italian pre-schoolers. 119 preschool children (3-6 years old) from 3 Italian kindergartens were included in this study. The schools were randomly allocated to intervention and control group. Movement Assessment Battery for Children - 2 (MABC-2) was administered to all the children at the baseline and at one-month follow-up. During this month, the schools assigned to the control group followed the normal curriculum; the schools assigned to the Animal Fun group, followed the Animal Fun activity (thirty minutes, thrice a week). The investigators expect that the Animal Fun program demonstrates valid and feasible even in the Italian context, where there is lack of movement program supporting the development of the pre-school children.

NCT ID: NCT04714242 Completed - Clinical trials for Polypoidal Choroidal Vasculopathy

OCTA and Polypoidal Choroidal Vasculopathy

Start date: January 15, 2019
Phase:
Study type: Observational

To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.

NCT ID: NCT04714021 Recruiting - Gastrostomy Clinical Trials

CO2 vs Air Insufflation in Children Undergoing PEG

Start date: January 7, 2021
Phase: N/A
Study type: Interventional

Ap¬plications of CO2 insufflation for endoscopic procedures have been reported for the performance of routine colonoscopy, small bowel endoscopy, endoscopic retro¬grade cholangiopancreatography (ERCP) and endoscopic submucosal dissection in the upper and lower gastrointestinal tracts. These studies showed that CO2 insufflation reduces the post-procedural abdominal distension and pain without CO2 retention and adverse events. However, there has been no report on the safety and efficacy of CO2 insufflation in PEG procedures in adults or in children. In the present study, we would like to evaluate by randomized controlled trial: the safety of the CO2 insufflation during PEG and the inhibi¬tory effects of CO2 insufflation on bowel distension after PEG.

NCT ID: NCT04712669 Completed - Clinical trials for Pulmonary Arterial Hypertension

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)

Start date: March 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.

NCT ID: NCT04712448 Active, not recruiting - Healthy Clinical Trials

Serum Prevalence of SARS-Cov-2 Antibodies in Pre-pandemic Blood Samples (SPARE)

SPARE
Start date: December 30, 2020
Phase:
Study type: Observational

The first reports of infections caused by SARS-CoV-2 were released from Wuhan, China in December 2019. From there, the infection quickly spread into a pandemic form. The clinical manifestation of the infection varies enormously, from totally asymptomatic or mildly symptomatic forms, with nonspecific and flu-like manifestations, to an acute respiratory distress syndrome which, in patients requiring hospitalization in the ICU and mechanical ventilation invasive, can lead to death, especially in elderly subjects and carriers of co-morbidities. Recently, the association of blood groups ABO as possible biological markers of susceptibility to COVID-19, has been evaluated, linking blood type O with a lower chance of infection, blood type A with the highest risk, and blood group B with the greatest complications. In Italy, the first non "imported" case dates back to February 2020, although new evidence on subjects tested positive for the antibody assay on serum samples suggests that the virus started to circulate before the official date. Few are the data relating to asymptomatic infections or with mild non-specific and nuanced symptoms that have been quantified in about 85% of the total number of infected. Moreover, thanks to the availability of serological tests that identify the presence of anti-SARS-CoV-2 antibodies, it emerged that a proportion of the population was infected by the virus and developed an antibody response and that almost 30% of the people with antibodies were asymptomatic. In order to evaluate the seroprevalence of COVID-19 infection among asymptomatic subjects the investigators will conduct specific serological tests (total antibodies) to identify the prevalence of SARS-2-CoV antibodies among healthy blood donors who went to transfusion facilities of the DIMT in Venice during the pandemic (about 2500 periodic donors who referred to the Transfusion Center in the period between May and October 2019). Patients afferent to the Interinstitutional Multidisciplinary Biobank (BioBIM) of the Research Center of the IRCCS San Raffaele Pisana in Rome, with or without concomitant co-morbidities (about 1000 subject) will be also tested. All samples will be analyzed for any association with sex, age group and blood group.

NCT ID: NCT04712422 Completed - Clinical trials for Myotonic Dystrophy 1

Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1

CABLAMYD
Start date: October 27, 2020
Phase:
Study type: Observational

Impairment of balance and gait are frequent complaints in patients with myotonic dystrophy type 1 (DM1). In these persons, there is an increased risk for stumbles and falls when compared to normal subjects. An underestimated cause of falls might be the weakness of neck flexor muscles (due to cervical ataxia). It is well known that fibres of muscle spindles are receptors combining a specialized sub-set of muscle fibers with a specialized array of both sensory and motor nerve fibers. Spindles transduce into neural afferent discharges the muscle length and length changes. They are very dense in deep neck muscles, are crucial to body balance and gage orientation, and are severely affected in DM1. Preliminary results suggest that falls could reflect imbalance. These indicate that cervical ataxia may come into play because of muscle spindle fibre disruption. In light of the current knowledge on the physiology of balance and on the association between balance deficits and cervical dystonia in other clinical conditions (e.g., whiplash injury), a rationale is therefore offered to a confirmation of the hypothesis that DM1 patients may suffer from cervical ataxia. The primary endpoint is the demonstration of an association between balance deficits in standing and cervical proprioception deficit in adults affected by Myotonic dystrophy 1. Secondary endpoints are: - the investigation of the correlation among the two deficits and the clinical conditions of patients, - the definition of normative data in the measure of cervical proprioception in a sample of healthy participants. It is expected that high scores in postural balance, obtained on the posturographic Equitestâ„¢-Sensory Organization Test-SOT, correspond to high levels of repositioning accuracy in tests of cervical repositioning and low SOT scores correspond to low accuracy. Moreover, it is expected that an association exists among the two deficits and the clinical situation of the patients. Results from the present pilot study will allow an estimate of the sample size for future experimental protocols. The evidence for an association between balance deficits and cervical ataxia would be of obvious relevance to the patients. This would also support the hypothesis that neck muscle spindles may be especially affected in DM1. This would highlight that muscles are also crucial sensory organs, involved in the perception of joint position, muscle strength, and fatigue. Results from the present study might allow the definition of new rehabilitative programs, such as treatments through a neck strengthening (and thus stiffening) exercise program. This study, therefore, might stimulate new research hypothesis at the neurophysiologic level and possibly lead to findings generalizable from DM1 to other forms of myopathy.

NCT ID: NCT04712292 Recruiting - Clinical trials for Colorectal Neoplasms Malignant

Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer

COVID-CRC
Start date: September 8, 2020
Phase:
Study type: Observational

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been identified as the cause of the Coronavirus disease 19 (COVID-19), which was initially reported in December 2019 in China and has since rapidly spread worldwide. Since then, the COVID-19 pandemic has caused a detrimental effect of the national health care system, causing a drastic reduction of the screening programs for colorectal cancer and requiring the redistribution of the hospital resources from elective surgery to the care of patients with SARS-Cov_2 infection requiring admission.

NCT ID: NCT04712253 Completed - Biliary Condition Clinical Trials

International Study to Evaluate Outcomes and Safety of Patients Undergoing ERCP Using a Single-use Cholangioscope and Single-use Duodenoscope

MESE
Start date: January 27, 2021
Phase:
Study type: Observational

Since its introduction more than 40 years ago, endoscopic retrograde cholangiopancreatography (ERCP) has fundamentally changed the treatment of biliopancreatic diseases. Since late 1970s there have been sporadic reports of nosocomial infections linked to endoscopic procedures, the majority caused by inadequate reprocessing of endoscopes. Infections due to multidrug-resistant organisms (MDROs) however have increasingly become a concern in health care, including in gastrointestinal (GI) endoscopy. Since 2010, reports of individual cases and serial outbreaks of MDRO infections associated with ERCP have been published worldwide. This is because, unlike a gastroscope or colonoscope, the duodenoscope is a complex instrument with unique mechanical features incorporated at the distal tip. This includes a recessed space containing an elevator, a wire cable that moves the elevator, working channel, and most recently, a seal that prevents contamination of the elevator wire channel. This complex design creates hard-to-reach areas that make optimal mechanical cleaning and disinfection difficult. With the aim of overcoming these issues, a single-use duodenoscope (EXALT Model D, Boston Scientific Corporation, Marlborough, Massachusetts, USA) has been developed in the United States of America (USA) and approved by the United States Food and Drug Administration (FDA) for clinical use in December 2019. Different studies evaluating this new device, including randomized clinical trials (RCTs), have already been published, which have confirmed that single-use duodenoscopes represent an alternative to reusable duodenoscopes for performing low-complexity ERCP procedures in experienced hands. Digital Single Operator Cholangioscopy (D-SOC) using the single use Spyglass DS II (Boston Scientific Corporation, Marlborough, Massachusetts, USA) is a diagnostic and therapeutic modality which allows for direct endoscopic visualization of the biliopancreatic ductal system. The principal diagnostic indication of D-SOC are bile duct or pancreatic strictures and unclear filling defects, adding direct endoscopic appearance data to biopsy sampling or brush cytology in order to improve the diagnostic yield. The major therapeutic indication for D-SOC is lithotripsy for difficult biliary and pancreatic stones. However, cholangioscopy increased the risk of post ERCP cholangitis. Bacteremia was suggested to be specifically related to cholangioscopy in 13.9% of 72 patients, based on serial blood samplings, and to be associated with biopsy sampling and strictures. For this reason, the recent European Society of Gastrointestinal Endoscopy (ESGE) guideline suggests that patients should be considered to be at high risk for post-ERCP cholangitis when cholangioscopy is performed. Presently, there are very few clinical reports about technical and clinical outcome of ERCPs performed with single use duodenoscope and there is complete lack of data about efficacy, safety and adverse events of the combination of the new single-use duodenoscope and the Spyglass DS II. The aim of this multicentric retrospective study was to evaluate the technical success, clinical outcome and rate of adverse events of this procedure.